Feb 20, 2024 7:30am EST Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
Dec 27, 2023 7:30am EST Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
Dec 21, 2023 7:30am EST Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
Nov 08, 2023 4:05pm EST Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
Nov 07, 2023 7:30am EST Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
Nov 01, 2023 7:00am EDT Matinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023
Oct 11, 2023 7:30am EDT Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution
